ZNF767P

Across TCGA pan-cancer cohorts, ZNF767P RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of ZNF767P’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where ZNF767P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ZNF767P is over-expressed in tumor, although a few such as BRCA and KICH show the opposite, repressed pattern.

LIHC, COAD, and CHOL are the cancer types where ZNF767P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ZNF767P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+1.219	<.001	9	view →
COAD	All	II,III,IV	+0.653	<.001	9	view →
CHOL	Female	All	+2.553	<.001	5	view →
READ	All	All	+0.773	.010	4	view →
BRCA	Female	All	−0.404	<.001	4	view →
KIRC	All	All	+0.262	.005	4	view →
KICH	All	All	−0.609	<.001	3	view →
BLCA	All	All	+0.415	.030	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

ZNF767P–LIHC

Open the LIHC breakdown →